Day 1 - Thu, Sep 11 |
Agora
|
09:00-10:17 |
ENG
Moderated Poster 1
|
Hyun-Jai Cho (Seoul National Univ., Korea)
|
09:00-09:07 |
Temporal Trends of Patient Characteristics and Clinical Outcomes in Heart Failure Patients: A Systematic Review and Meta-Regression Analysis
|
|
Joon-Seok Kim (The Catholic Univ., Korea)
|
09:07-09:14 |
Integrating Epigenetic Enhancer Activity and RNA Translation to Predict Fibrosis Reversibility in Heart Failure: A Deep Learning Approach
|
|
Rifaldy Fajar (IMCDS-BRF, Indonesia)
|
09:14-09:21 |
Balancing Blood Pressure and Catecholamine Support Is Critical in Cardiogenic Shock Patients
|
|
Benedikt Beer (Karolinska Institutet, Sweden)
|
09:21-09:28 |
Phenomapping-Derived Tool to Individualize the Effect of Sacubitril/Valsartan in Heart failure with Preserved Ejection Fraction
|
|
Minjae Yoon (Seoul National Univ., Korea)
|
09:28-09:35 |
Myocardial Tissue Characteristics and Left Ventricular Reverse Remodeling in Non-ischemic Dilated Cardiomyopathy Implemented with Ivabradine
|
|
Jooyeon Lee (Yonsei Univ., Korea)
|
09:35-09:42 |
Association of Steatotic Liver Disease Subtypes with the Clinical Expression of Hypertrophic Cardiomyopathy: Insights from a Nationwide Cohort Study
|
|
Yuran Ahn (The Catholic Univ., Korea)
|
09:42-09:49 |
Effects of Guideline-directed Medical Therapy Adherence on Mortality and Fatal Arrhythmias in Ischemic and Non-ischemic Heart Failure with Reduced Ejection Fraction: A National Cohort Analysis
|
|
Moojun Kim (Yonsei Univ., Korea)
|
09:49-09:56 |
Peak VO₂ as a Predictor of Outcomes in Contemporary Heart Failure Care: Insights From a Multicentre Retrospective Cohort
|
|
Natsumi Kashimura (Juntendo Univ., Japan)
|
09:56-10:03 |
Impact of ECMO Support on Organ Donation and Transplant Outcomes
|
|
Jihyuk Chung (Sungkyunkwan Univ., Korea)
|
10:03-10:10 |
Comparing Neighborhood and Individual Socioeconomic Risk Factors in Heart Failure Prognosis: Data from the Swedish Heart Failure Registry
|
|
Valente Valeria (Karolinska Institutet, Sweden)
|
10:10-10:17 |
The Emerging Miracle Drug in Acute Heart Failure
|
|
Farrukh Malik (National Institute of Cardiovascular Diseases, Pakistan)
|